Presenters
Rodney Hicks, MD*
Chief Medical Officer and Nuclear Medicine specialist, Melbourne Theranostics Innovation Centre
Paul Yonover, MD*
Chief Data Officer and Director of Clinical Navigation, UroPartners, Chicago
David N. Cade, MD
Telix Group Chief Medical Officer
Darren Patti, PharmD
Telix Group Chief Operating Officer
*Independent expert speakers are not employees of Telix. Views are speaker's own.
3
68Ga-PSMA-11: Extensive published data and real-world experience1-9
Overall ≥80% sensitivity and ≥90% specificity,
based on a review of 76 published articles in >5,000 patients9
High true positive rates of detection for regional and distant metastases including bone and soft tissue1-5,8,9
High diagnostic performance for micrometastatic disease as small as 2 mm and very low PSA values (0.02 ng/mL)4,8,9
High diagnostic performance in pelvic bed, lymph nodes, and bladder neck9-11
High reproducibility and inter-reader agreement3,6,7
PET, positron emission tomography; PSA, prostate-specific antigen.
1. Rauscher I, et al. J Nucl Med. 2020;61(1):51-57. 2. Kroenke M, et al. J Nucl Med. 2021;62(8):1082-1088. 3. Illuccix prescribing information. Telix Pharmaceuticals; 2023. 4. Burgard C, et al. Cancers (Basel). 2023;15(5):1376. 5. Hagens MJ, et al. J Nucl Med. 2022;63(10):1531-1536. 6. Giesel FL, et al. Eur J Nucl Med Mol Imaging. 2015;42(12):1794-1800. 7. van Leeuwen PJ, et al. BJU Int. 2017;119(2):209-215. 8. Alipour R, et al. Ther Adv Med Oncol. 2019;11:1758835919876828. 9. Purysko AS, et al. Appl Radiol. 2024; 53(2):22-35. 10. Pallavi UN, et al. Indian J Nucl Med. 2020;35(2):93-99. 11. Yilmaz B, et al. Prostate. 2019;79(9):1007-1017.
4
Recent data: Illuccix China Phase 3 study (December 2025)
High PPV, including at low PSA values and across differing metastatic locations
Primary endpoint met decisively in 140 pts
Overall patient-level PPV of 94.8% for the detection of tumors with TLX591-Px (95% CI: 85.9%, 98.2%), with the lower
bound of the 95% CI (85.9%).
Significantly exceeded predefined threshold of 60%
Region-level PPV
100.0% in the prostate bed, extra-pelvic soft tissue, lymph nodes, and organ metastases (non-bone)
94.7% in the pelvic region outside of the prostate bed, including lymph nodes
87.0% in bone metastases
High PPV in all PSA strata
Baseline PSA (ng/mL) | PPV (95% CI) |
≥ 5.0 | 100.0% (78.5%, 100.0%) |
< 5.0 to 2.0 | 100.0% (67.6%, 100.0%) |
< 2.0 to 1.0 | 90.9% (62.3%, 98.4%) |
< 1.0 to 0.5 | 90.0% (59.6%, 98.2%) |
< 0.5 to 0.2 | 93.3% (70.2%, 98.8%) |
Meaningful impact on clinical decision-making More than two-thirds (67.2%) of patients experienced a change in their treatment plan following TLX591-Px PSMA-PET imaging compared with the initial plan at baseline
1. Telix ASX disclosure December 22, 2025. Illuccix China Phase 3 Registration Study Clinical Study Report, December 2025.
5
68Ga-PSMA-11 PET detection in patients with very low PSA
Too Small? Technology and Technique Are the Answers
32-minute SFOV
4-minute EFOV
1-minute EFOV
30-second EFOV
Same patient Same PSA Same tracer
2 weeks apart
Conventional 60-min uptake
Optimised >120-min post-diuretic uptake
Patient representative scan - individual results may vary.
6
Gallium-68: Structural market leadership
A proven, scalable platform built for sustained growth
Multiple global generator manufacturers (and growing)
Multiple established and reliable sources of parent germanium-68
Convenient, dependable, on-demand and on-site access
Higher activity generators entering the market = scheduling flexibility and production efficiencies
Commercially available solid and liquid target solutions available for cyclotron produced material
Yields >5 Ci per production with ARTMS QIS®
Robust and cost-efficient suppliers of parent zinc-68 for target production
7
Gozellix grows Telix share by increasing access and efficiency
362 additional cameras in range
164 cameras can increase scan volumes
*Within 10 miles of current limit
Newly in range
Efficiency for accounts = more volume at more accounts
Allows for two product
strategy
8
Contact:
Kyahn Williamson
SVP Investor Relations and Corporate Communications
kyahn.williamson@telixpharma.com
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
Attachments
- Original document
- Permalink
Disclaimer
Telix Pharmaceuticals Ltd. published this content on March 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 05, 2026 at 01:47 UTC.
